A Phase 3, Randomized, Double-Blind, 52-week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, 52-week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants with Nonsegmental Vitiligo
At Pivotal Research we are dedicated to improving patient care and advancing medical knowledge through cutting-edge clinical trials and research.